Insider Selling: Roivant Sciences (NASDAQ:ROIV) Insider Sells $10,320,628.75 in Stock

by · The Markets Daily

Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) insider Mayukh Sukhatme sold 284,707 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $36.25, for a total transaction of $10,320,628.75. Following the sale, the insider directly owned 18,630,739 shares of the company’s stock, valued at $675,364,288.75. The trade was a 1.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Mayukh Sukhatme also recently made the following trade(s):

  • On Friday, August 14th, Mayukh Sukhatme sold 243,177 shares of Roivant Sciences stock. The stock was sold at an average price of $36.23, for a total value of $8,810,302.71.
  • On Tuesday, August 18th, Mayukh Sukhatme sold 136,942 shares of Roivant Sciences stock. The shares were sold at an average price of $36.73, for a total value of $5,029,879.66.

Roivant Sciences Price Performance

ROIV stock opened at $36.84 on Friday. Roivant Sciences Ltd. has a 1-year low of $11.54 and a 1-year high of $37.97. The firm has a fifty day moving average price of $34.48 and a two-hundred day moving average price of $30.38. The firm has a market cap of $26.61 billion, a price-to-earnings ratio of -69.51 and a beta of 1.12.

Roivant Sciences (NASDAQ:ROIV – Get Free Report) last posted its earnings results on Friday, August 7th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.04. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%.The company had revenue of $1.44 million during the quarter, compared to analyst estimates of $2.06 million. As a group, analysts expect that Roivant Sciences Ltd. will post -2 EPS for the current fiscal year.

Institutional Investors Weigh In On Roivant Sciences

A number of institutional investors have recently bought and sold shares of the business. SBI Securities Co. Ltd. lifted its position in shares of Roivant Sciences by 1,740.3% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock worth $27,000 after purchasing an additional 1,166 shares in the last quarter. Allworth Financial LP grew its position in Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after purchasing an additional 583 shares in the last quarter. Kestra Advisory Services LLC purchased a new position in Roivant Sciences during the fourth quarter valued at approximately $47,000. Parallel Advisors LLC increased its stake in Roivant Sciences by 33.7% in the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock valued at $57,000 after buying an additional 520 shares during the period. Finally, CIBC Private Wealth Group LLC increased its stake in Roivant Sciences by 7,614.3% in the 4th quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock valued at $59,000 after buying an additional 2,665 shares during the period. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Leerink Partners set a $42.00 price objective on shares of Roivant Sciences in a report on Thursday, May 21st. Bank of America restated a “neutral” rating on shares of Roivant Sciences in a research report on Friday, July 31st. Piper Sandler restated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, May 21st. HC Wainwright upped their price target on shares of Roivant Sciences from $34.00 to $41.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Finally, TD Cowen reiterated a “buy” rating on shares of Roivant Sciences in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.14.

View Our Latest Stock Report on Roivant Sciences

Roivant Sciences Company Profile

(Get Free Report)

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.

See Also